ImmuCell Q4 2023 EPS $(0.15) Up From $(0.22) YoY; Product Sales $5.1M Up From $3.9M YoY
$ICCC
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Health Care
ImmuCell Q4 2023 EPS $(0.15) Up From $(0.22) YoY; Product Sales $5.1M Up From $3.9M YoY
Save time and jump to the most important pieces.
With U.S. stock futures trading mixed this morning on Wednesday, some of the stocks that may grab investor focus today are as follows: Wall Street expects Manchester United Plc. (NYSE:MANU) to report a quarterly loss at 27 cents per share on revenue of $162.92 million before the opening bell, according to data from Benzinga Pro. Manchester United shares gained 1.6% to $16.19 in the after-hours trading session. Kura Sushi USA (NASDAQ:KRUS) posted downbeat results for its third quarter on Tuesday. Kura Sushi shares fell 4.2% to $56.00 in the after-hours trading session. Analysts are expecting PriceSmart, Inc. (NASDAQ:PSMT) to post quarterly earnings at $1.01 per share on revenue of $
10-Q - IMMUCELL CORP /DE/ (0000811641) (Filer)
8-K - IMMUCELL CORP /DE/ (0000811641) (Filer)
8-K - IMMUCELL CORP /DE/ (0000811641) (Filer)
PORTLAND, Maine, June 21, 2023 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced that Bryan K. Gathagan has been appointed to its Board of Directors. Mr. Gathagan is the owner and a managing member of broad Thinking, LLC, a management consulting firm and has 25 years of animal health experience. He is a founding member of Animalytix LLC and has served as its Chief Financial and Chief Technology Officer since it began operations in 2010. Prior to Animalytix
SC 13D - IMMUCELL CORP /DE/ (0000811641) (Subject)
SC 13D/A - IMMUCELL CORP /DE/ (0000811641) (Subject)
SC 13G/A - IMMUCELL CORP /DE/ (0000811641) (Subject)
PORTLAND, Maine, Nov. 13, 2024 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced its unaudited financial results for the quarter ended September 30, 2024. Q3 2024 Highlights: Product sales increased 11% over the comparable quarter in 2023.Product sales increased 51% over the comparable nine-month period in 2023.Product sales increased 46% over the previous trailing twelve-month period ended September 30, 2023. Management's Discussion:"Our preliminary, un
PORTLAND, Maine, Nov. 07, 2024 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, expects to report unaudited financial results for the quarter ended September 30, 2024 after the market closes on Wednesday, November 13, 2024. The Company is planning to host a conference call the next morning, Thursday, November 14, 2024, at 9:00 AM ET to review the unaudited financial results. Interested parties can access the conference call by dialing (844) 855-9502 (toll free) or (412)
PORTLAND, Maine, Oct. 08, 2024 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced preliminary, unaudited sales results for the third quarter of 2024, which ended September 30, 2024. Preliminary, Unaudited Total Sales Results: 20242023$ Increase % IncreaseDuring the Three-Month Periods Ended September 30,$6.0 million$5.4 million$615,00011% During the Nine-Month Periods Ended September 30,$18.7 million$12.4 million$6.4 million51% During the Twelve-Mont
PORTLAND, Maine, Nov. 13, 2024 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced its unaudited financial results for the quarter ended September 30, 2024. Q3 2024 Highlights: Product sales increased 11% over the comparable quarter in 2023.Product sales increased 51% over the comparable nine-month period in 2023.Product sales increased 46% over the previous trailing twelve-month period ended September 30, 2023. Management's Discussion:"Our preliminary, un
PORTLAND, Maine, Nov. 07, 2024 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, expects to report unaudited financial results for the quarter ended September 30, 2024 after the market closes on Wednesday, November 13, 2024. The Company is planning to host a conference call the next morning, Thursday, November 14, 2024, at 9:00 AM ET to review the unaudited financial results. Interested parties can access the conference call by dialing (844) 855-9502 (toll free) or (412)
PORTLAND, Maine, Oct. 08, 2024 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced preliminary, unaudited sales results for the third quarter of 2024, which ended September 30, 2024. Preliminary, Unaudited Total Sales Results: 20242023$ Increase % IncreaseDuring the Three-Month Periods Ended September 30,$6.0 million$5.4 million$615,00011% During the Nine-Month Periods Ended September 30,$18.7 million$12.4 million$6.4 million51% During the Twelve-Mont
4 - IMMUCELL CORP /DE/ (0000811641) (Issuer)
4 - IMMUCELL CORP /DE/ (0000811641) (Issuer)
4 - IMMUCELL CORP /DE/ (0000811641) (Issuer)